Back to search results

Retrospective Review of Esophageal Cancer at MSKCC

This study is looking back at information from patients who have had surgery (esophagectomy) for esophageal cancer. Researchers want to understand if the amount of tumor left at the edges of the removed tissue, specifically the circumferential resection margin (CRM), affects how long patients live without their cancer returning (progression-free survival) and overall survival. You might be eligible if you are 18 or older, have been diagnosed with esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC), and had a specific type of tumor (pT3) removed during your esophagectomy. The study aims to include about 4000 participants. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers are reviewing existing patient data. It aims to include 4000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at survival outcomes for up to 2 years after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05706558

Retrospective Review of Esophageal Cancer at MSKCC

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~4,000 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:Esophagectomy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
Measured over Up to 2 years

Conditions

Esophageal Cancer
Esophagus Cancer

Explore related trials

Esophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma

NCT05706558

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Daniela Molena, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Daniela Molena, MD
[email protected]
212-639-3870
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
Pathologic staged T3 tumors (pT3)

Exclusion

Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
Patients undergoing salvage esophagectomy
Evidence of distant metastatic disease
Patients with a positive proximal or distal margin

What this trial measures

  • . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)Up to 2 years

    Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.